Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm-Reference-Cited by-同舟云学术

Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm

Published:2011-09-22 Issue:12 Volume:86 Page:974-979
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Rumi Elisa,Harutyunyan Ashot,Elena Chiara,Pietra Daniela,Klampfl Thorsten,Bagienski Klaudia,Berg Tiina,Casetti Ilaria,Pascutto Cristiana,Passamonti Francesco,Kralovics Robert,Cazzola Mario

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.22166/fullpdf

Reference40 articles.

1. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera;James;Nature,2005

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

3. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis;Levine;Cancer Cell,2005

4. A gain-of-function mutation of JAK2 in myeloproliferative disorders;Kralovics;N Engl J Med,2005

5. The myeloproliferative disorders;Campbell;N Engl J Med,2006

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression;International Journal of Molecular Sciences;2024-04-05

2. Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification ofDYRK1A;2023-12-10

3. Shared and distinct genetic etiologies for different types of clonal hematopoiesis;Nature Communications;2023-09-08

4. Sclerosing extramedullary hematopoietic tumor of the colon: A case report and literature review;Experimental and Therapeutic Medicine;2023-02-10

5. Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond;Blood Reviews;2022-09